NO20060948L - Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den - Google Patents

Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den

Info

Publication number
NO20060948L
NO20060948L NO20060948A NO20060948A NO20060948L NO 20060948 L NO20060948 L NO 20060948L NO 20060948 A NO20060948 A NO 20060948A NO 20060948 A NO20060948 A NO 20060948A NO 20060948 L NO20060948 L NO 20060948L
Authority
NO
Norway
Prior art keywords
crystalline form
preparation
pharmaceutical compositions
compositions containing
ivabradine hydrochloride
Prior art date
Application number
NO20060948A
Other languages
English (en)
Other versions
NO338481B1 (no
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damen
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060948(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20060948L publication Critical patent/NO20060948L/no
Publication of NO338481B1 publication Critical patent/NO338481B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

(-krystallinsk form av ivabradin-hydroklond med formel (I) kjennetegnet ved dens pulverrøntgendiffraksjonsdiagram Medikamenter
NO20060948A 2005-02-28 2006-02-27 γ-krystallinsk form av ivabradin-hydroklorid, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den NO338481B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
NO20060948L true NO20060948L (no) 2006-08-29
NO338481B1 NO338481B1 (no) 2016-08-22

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060948A NO338481B1 (no) 2005-02-28 2006-02-27 γ-krystallinsk form av ivabradin-hydroklorid, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den

Country Status (42)

Country Link
US (3) US7361650B2 (no)
EP (1) EP1707562B1 (no)
JP (1) JP4628974B2 (no)
KR (1) KR100835447B1 (no)
CN (1) CN100402502C (no)
AP (1) AP1956A (no)
AR (1) AR052926A1 (no)
AT (1) ATE396974T1 (no)
BR (1) BRPI0600796B8 (no)
CA (1) CA2537400C (no)
CO (1) CO5770097A1 (no)
CR (1) CR8249A (no)
CU (1) CU23616B7 (no)
CY (1) CY1109010T1 (no)
DE (1) DE602006001312D1 (no)
DK (1) DK1707562T3 (no)
EA (1) EA008465B1 (no)
ES (1) ES2308689T3 (no)
FR (1) FR2882555B1 (no)
GE (1) GEP20084467B (no)
GT (1) GT200600088A (no)
HK (1) HK1096659A1 (no)
HR (1) HRP20080406T5 (no)
IL (1) IL173959A0 (no)
JO (1) JO2515B1 (no)
MA (1) MA28134A1 (no)
ME (1) ME02747B (no)
MY (1) MY158129A (no)
NO (1) NO338481B1 (no)
NZ (1) NZ545578A (no)
PE (1) PE20061142A1 (no)
PL (1) PL1707562T3 (no)
PT (1) PT1707562E (no)
RS (1) RS50598B (no)
SA (1) SA06270040B1 (no)
SG (1) SG125229A1 (no)
SI (1) SI1707562T1 (no)
TW (1) TWI314143B (no)
UA (1) UA86595C2 (no)
UY (1) UY29406A1 (no)
WO (1) WO2006092492A1 (no)
ZA (1) ZA200601764B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
PT2471780E (pt) 2007-05-30 2015-02-24 Ind Swift Lab Ltd Sais oxalato de ivabradina cristalinos e seus polimorfos
CN102264689B (zh) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2534135A2 (en) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP2773621B1 (en) 2011-11-04 2015-12-30 Synthon BV A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
SI2781509T2 (sl) * 2013-03-19 2023-10-30 Chemo Research, S.L. Novi polimorf ivabradin hidroklorida in postopek za njegovo pripravo
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
WO2020092288A1 (en) 2018-10-30 2020-05-07 Amgen Inc. Process of making ivabradine hydrochloride drug product
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
US20080153803A1 (en) 2008-06-26
CR8249A (es) 2008-01-21
AR052926A1 (es) 2007-04-11
MA28134A1 (fr) 2006-09-01
UY29406A1 (es) 2006-07-31
AP1956A (en) 2009-02-18
EP1707562A1 (fr) 2006-10-04
EP1707562B1 (fr) 2008-05-28
ME02747B (me) 2010-05-07
DK1707562T3 (da) 2008-10-13
DE602006001312D1 (de) 2008-07-10
IL173959A0 (en) 2006-07-05
AU2006200857A1 (en) 2010-01-28
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
HRP20080406T5 (en) 2008-11-30
GT200600088A (es) 2006-10-24
CU23616B7 (es) 2011-01-27
FR2882555A1 (fr) 2006-09-01
GEP20084467B (en) 2008-08-25
PL1707562T3 (pl) 2008-08-29
US7867996B2 (en) 2011-01-11
PE20061142A1 (es) 2006-12-30
TW200640872A (en) 2006-12-01
CA2537400C (fr) 2009-12-15
BRPI0600796A (pt) 2007-08-14
PT1707562E (pt) 2008-07-08
CU20060037A7 (es) 2008-06-30
ATE396974T1 (de) 2008-06-15
HK1096659A1 (en) 2007-06-08
NZ545578A (en) 2007-02-23
MY158129A (en) 2016-08-30
FR2882555B1 (fr) 2007-05-04
WO2006092492A1 (fr) 2006-09-08
BRPI0600796B1 (pt) 2019-02-19
US20090318417A1 (en) 2009-12-24
SG125229A1 (en) 2006-09-29
NO338481B1 (no) 2016-08-22
SI1707562T1 (sl) 2008-10-31
JP4628974B2 (ja) 2011-02-09
CO5770097A1 (es) 2007-06-29
ZA200601764B (en) 2007-05-30
CY1109010T1 (el) 2014-07-02
RS50598B (sr) 2010-05-07
US7361650B2 (en) 2008-04-22
KR20060095499A (ko) 2006-08-31
SA06270040B1 (ar) 2010-03-23
EA200600320A1 (ru) 2006-08-25
EA008465B1 (ru) 2007-06-29
BRPI0600796B8 (pt) 2021-05-25
US20060194963A1 (en) 2006-08-31
JP2006241156A (ja) 2006-09-14
CN1827602A (zh) 2006-09-06
HRP20080406T3 (en) 2008-09-30
TWI314143B (en) 2009-09-01
KR100835447B1 (ko) 2008-06-09
ES2308689T3 (es) 2008-12-01
UA86595C2 (ru) 2009-05-12
JO2515B1 (en) 2010-03-17
AP2006003521A0 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
NO20060948L (no) Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060946L (no) β-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060949L (no) yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den
NO20064596L (no) Delta-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060947L (no) β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063518L (no) Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
UA89905C2 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕЕ СОДЕРЖИТ
JO2501B1 (en) The crystalline form of gamma-D of ivabradine hydrochloride, its preparation process and its pharmaceutical ingredients
CU23678B7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen
GEP20094652B (en) New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
UY29855A1 (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen